Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.

Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B.

Cancers (Basel). 2020 Feb 18;12(2). pii: E473. doi: 10.3390/cancers12020473.

PMID:
32085544
2.

Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage.

Icard P, Schussler O, Loi M, Bobbio A, Lupo AM, Wislez M, Iannelli A, Fournel L, Damotte D, Alifano M.

Cancers (Basel). 2020 Jan 22;12(2). pii: E266. doi: 10.3390/cancers12020266.

3.

[SMARCA4-deficient thoracic tumors: A new entity].

Decroix E, Leroy K, Wislez M, Fournel L, Alifano M, Damotte D, Mansuet-Lupo A.

Bull Cancer. 2020 Jan;107(1):41-47. doi: 10.1016/j.bulcan.2019.12.001. Epub 2020 Jan 6. Review. French.

PMID:
31916995
4.

Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?

Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B.

Cancers (Basel). 2019 Nov 13;11(11). pii: E1784. doi: 10.3390/cancers11111784.

5.

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K.

J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3.

6.

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.

Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L.

EBioMedicine. 2019 Oct;48:191-202. doi: 10.1016/j.ebiom.2019.09.003. Epub 2019 Oct 21.

7.

[Guidelines for the macroscopic management of surgically resected lung carcinoma].

Mansuet-Lupo A, Filaire M, Chaffanjon P, Alifano M, Forest F, Gibault L, Vignaud JM, Brevet M, Hofman V, Rouquette I, Antoine M, Cazes A, Damotte D, Lantuejoul S; pour le groupe de pathologistes thoraciques de valorisation de l’expertise, de la recherche et de l’innovation (PATTERN), Fondation Synergie Lyon Cancer.

Ann Pathol. 2019 Dec;39(6):425-432. doi: 10.1016/j.annpat.2019.05.008. Epub 2019 Oct 8. French.

PMID:
31604575
8.

Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study.

Yannoutsos A, Fontaine M, Galloula A, Damotte D, Chatellier G, Paterlini-Bréchot P, Meyer G, Pastre J, Duchatelle V, Marini V, Schwering KL, Lazareth I, Ghaffari P, Stansal A, Sanson H, Labrousse C, Beaussier H, Nasr NB, Zins M, Salmeron S, Messas E, Lajonchère JP, Emmerich J, Priollet P, Trédaniel J.

BMC Cardiovasc Disord. 2019 Sep 13;19(1):212. doi: 10.1186/s12872-019-1193-1.

9.

PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer.

Pignot G, Le Goux C, Vacher S, Schnitzler A, Radvanyi F, Allory Y, Lallemand F, Delongchamps NB, Zerbib M, Terris B, Damotte D, Bieche I.

Oncol Lett. 2019 Oct;18(4):3471-3480. doi: 10.3892/ol.2019.10706. Epub 2019 Aug 2.

10.

Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.

Jouinot A, Ulmann G, Vazeille C, Durand JP, Boudou-Rouquette P, Arrondeau J, Tlemsani C, Fournel L, Alifano M, Wislez M, Chapron J, Le Bris C, Mansuet-Lupo A, Damotte D, Neveux N, De Bandt JP, Alexandre J, Cynober L, Goldwasser F.

Clin Nutr. 2019 Aug 10. pii: S0261-5614(19)30315-2. doi: 10.1016/j.clnu.2019.08.003. [Epub ahead of print]

PMID:
31443979
11.

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.

Fournel L, Wu Z, Stadler N, Damotte D, Lococo F, Boulle G, Ségal-Bendirdjian E, Bobbio A, Icard P, Trédaniel J, Alifano M, Forgez P.

Cancer Lett. 2019 Nov 1;464:5-14. doi: 10.1016/j.canlet.2019.08.005. Epub 2019 Aug 9.

PMID:
31404614
12.

Unexpected pulmonary tumour in a young woman.

Boulle G, Dupeux M, Charpentier MC, Larousserie F, Régnard JF, Damotte D, Mansuet-Lupo A.

J Clin Pathol. 2019 Nov;72(11):783. doi: 10.1136/jclinpath-2018-205259. Epub 2019 Jul 26. No abstract available.

13.

Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer.

Mazzella A, Loi M, Mansuet-Lupo A, Bobbio A, Blons H, Damotte D, Alifano M.

Clin Lung Cancer. 2019 Nov;20(6):405-411. doi: 10.1016/j.cllc.2019.06.003. Epub 2019 Jun 13.

PMID:
31281051
14.

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.

Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E.

Cancer Med. 2019 Aug;8(9):4330-4337. doi: 10.1002/cam4.2175. Epub 2019 Jun 14.

15.

Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.

Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R; LYSA.

Eur J Cancer. 2019 Jul;115:47-56. doi: 10.1016/j.ejca.2019.04.006. Epub 2019 May 10.

PMID:
31082693
16.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

17.

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.

Althammer S, Tan TH, Spitzmüller A, Rognoni L, Wiestler T, Herz T, Widmaier M, Rebelatto MC, Kaplon H, Damotte D, Alifano M, Hammond SA, Dieu-Nosjean MC, Ranade K, Schmidt G, Higgs BW, Steele KE.

J Immunother Cancer. 2019 May 6;7(1):121. doi: 10.1186/s40425-019-0589-x.

18.

DNA alteration-based classification of uveal melanoma gives better prognostic stratification than immune infiltration, which has a neutral effect in high-risk group.

Narasimhaiah D, Legrand C, Damotte D, Remark R, Munda M, De Potter P, Coulie PG, Vikkula M, Godfraind C.

Cancer Med. 2019 Jun;8(6):3036-3046. doi: 10.1002/cam4.2122. Epub 2019 Apr 25.

19.

Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.

Lantuejoul S, Damotte D, Hofman V, Adam J.

J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101. doi: 10.21037/jtd.2018.12.103. Review.

20.

Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.

Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, Le Hay C, Cremer I, Régnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, Blons H.

J Thorac Oncol. 2019 May;14(5):844-856. doi: 10.1016/j.jtho.2019.01.017. Epub 2019 Feb 2.

PMID:
30721797
21.

T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.

Belhadj M, Mansour D, Kaltenbach S, Deau-Fischer B, Franchi P, Tamburini J, Chapuis N, Damotte D, Kosmider O, Burroni B, Bouscary D.

Haematologica. 2019 Mar;104(3):e117-e120. doi: 10.3324/haematol.2018.205542. Epub 2018 Dec 20. No abstract available.

22.

Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells.

Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I.

Oncoimmunology. 2018 Oct 11;8(1):e1505174. doi: 10.1080/2162402X.2018.1505174. eCollection 2019.

23.

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.

Sarkozy C, Copie-Bergman C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, Salles G, Steidl C, Ghesquières H, Mottok A, Traverse-Glehen A.

Am J Surg Pathol. 2019 Mar;43(3):341-351. doi: 10.1097/PAS.0000000000001198.

PMID:
30540571
24.

Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management.

Loi M, Mazzella A, Mansuet-Lupo A, Bobbio A, Canny E, Magdeleinat P, Régnard JF, Damotte D, Trédaniel J, Alifano M.

Ann Thorac Surg. 2019 Apr;107(4):1053-1059. doi: 10.1016/j.athoracsur.2018.10.029. Epub 2018 Nov 23.

PMID:
30476480
25.

Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma.

Saade A, Carton E, Mansuet-Lupo A, Jouffroy R, Damotte D, Yera H, Revel MP, Goldwasser F.

Emerg Infect Dis. 2018 Dec;24(12):2375-2378. doi: 10.3201/eid2412.180355.

26.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.

27.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Review. French.

PMID:
30343945
28.

[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].

Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D.

Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. Review. French.

PMID:
30337201
29.

[Malignant pleural mesothelioma: The role of surgery].

Fournel L, Janet-Vendroux A, Canny-Hamelin E, Mansuet-Lupo A, Guinet C, Bobbio A, Damotte D, Alifano M.

Rev Pneumol Clin. 2018 Oct;74(5):351-358. doi: 10.1016/j.pneumo.2018.09.006. Epub 2018 Oct 11. Review. French.

PMID:
30316650
30.

Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.

Lheure C, Hoffmann C, Kramkimel N, Plée J, Franck N, Vanhaecke C, Goldman-Lévy G, Bataillon G, Damotte D, Dupin N, Aractingi S, Grange F, Guégan S.

Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028. No abstract available.

31.

[Analysis of immune microenvironment by multiplex immunohistochemistry in locally advanced non-small cell lung cancer: Principles and perspectives].

Boulle G, Velut Y, Boni A, Lupo A, Alifano M, Trédaniel J, Giraud P, Damotte D.

Cancer Radiother. 2018 Oct;22(6-7):688-693. doi: 10.1016/j.canrad.2018.07.031. Epub 2018 Aug 18. Review. French.

PMID:
30131267
32.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

33.

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Braud VM, Biton J, Becht E, Knockaert S, Mansuet-Lupo A, Cosson E, Damotte D, Alifano M, Validire P, Anjuère F, Cremer I, Girard N, Gossot D, Seguin-Givelet A, Dieu-Nosjean MC, Germain C.

Oncoimmunology. 2018 Jan 29;7(5):e1423184. doi: 10.1080/2162402X.2017.1423184. eCollection 2018.

34.

Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, Pilorge S, Salah S, Quentin A, Deau B, Franchi P, Vignon M, Mabille L, Nguyen C, Kirova Y, Varlet P, Edjlali M, Dezamis E, Hoang-Xuan K, Soussain C, Houillier C, Damotte D, Pallud J, Bouscary D, Tamburini J.

Oncotarget. 2018 Mar 30;9(24):16822-16831. doi: 10.18632/oncotarget.24706. eCollection 2018 Mar 30.

35.

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.

Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guérin M, Biton J, Ouakrim H, Régnier F, Lupo A, Alifano M, Damotte D, Donnadieu E.

Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050. doi: 10.1073/pnas.1720948115. Epub 2018 Apr 9.

36.

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

Lantuejoul S, Adam J, Girard N, Duruisseaux M, Mansuet-Lupo A, Cazes A, Rouquette I, Gibault L, Garcia S, Antoine M, Vignaud JM, Galateau-Sallé F, Sagan C, Badoual C, Penault-Llorca F, Damotte D; pour le groupe pathologistes thoraciques de valorisation de l’expertise, de la recherche et de l’innovation (PATTERN). Fondation Synergie Lyon Cancer.

Ann Pathol. 2018 Apr;38(2):110-125. doi: 10.1016/j.annpat.2018.01.007. Epub 2018 Mar 21. French.

PMID:
29571563
37.

Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.

Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC.

PMID:
29518341
38.

Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells.

Bennett Saidu NE, Bretagne M, Mansuet AL, Just PA, Leroy K, Cerles O, Chouzenoux S, Nicco C, Damotte D, Alifano M, Borghese B, Goldwasser F, Batteux F, Alexandre J.

Oncotarget. 2018 Jan 10;9(10):9088-9099. doi: 10.18632/oncotarget.24144. eCollection 2018 Feb 6.

39.

Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.

Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J.

Haematologica. 2018 Jul;103(7):e296-e299. doi: 10.3324/haematol.2017.185843. Epub 2018 Feb 22. No abstract available.

40.

Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy.

Peranzoni E, Bougherara H, Barrin S, Mansuet-Lupo A, Alifano M, Damotte D, Donnadieu E.

J Vis Exp. 2017 Dec 27;(130). doi: 10.3791/55709.

41.

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.

Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, Penault-Llorca F, Lantuéjoul S.

Ann Oncol. 2018 Apr 1;29(4):953-958. doi: 10.1093/annonc/mdy014.

42.

The Human Penis Is a Genuine Immunological Effector Site.

Sennepin A, Real F, Duvivier M, Ganor Y, Henry S, Damotte D, Revol M, Cristofari S, Bomsel M.

Front Immunol. 2017 Dec 14;8:1732. doi: 10.3389/fimmu.2017.01732. eCollection 2017.

43.

Anaplastic Kaposi's sarcoma: 5 cases of a rare and aggressive type of Kaposi's sarcoma.

Chapalain M, Goldman-Lévy G, Kramkimel N, Carlotti A, Franck N, Lheure C, Audard V, Avril MF, Marcelin AG, Damotte D, Terris B, Aractingi S, Dupin N.

Ann Dermatol Venereol. 2018 Jan;145(1):21-28. doi: 10.1016/j.annder.2017.09.593. Epub 2017 Dec 28.

PMID:
29290414
44.

Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection.

Belmellat N, Semerano L, Segueni N, Damotte D, Decker P, Ryffel B, Quesniaux V, Boissier MC, Assier E.

Front Immunol. 2017 Nov 14;8:1533. doi: 10.3389/fimmu.2017.01533. eCollection 2017.

45.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

46.

Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.

Lococo F, Torricelli F, Rossi G, Alifano M, Damotte D, Rapicetta C, Tamagnini I, Cavazza A, Piana S, Galeone C, Paci M, Ciarrocchi A.

Lung Cancer. 2017 Nov;113:93-101. doi: 10.1016/j.lungcan.2017.09.009. Epub 2017 Sep 18.

PMID:
29110857
47.

Thoracic Endometriosis Syndrome Other Than Pneumothorax: Clinical and Pathological Findings.

Bobbio A, Canny E, Mansuet Lupo A, Lococo F, Legras A, Magdeleinat P, Regnard JF, Gompel A, Damotte D, Alifano M.

Ann Thorac Surg. 2017 Dec;104(6):1865-1871. doi: 10.1016/j.athoracsur.2017.06.049. Epub 2017 Oct 17.

PMID:
29054304
48.

Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought.

Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, Terminella A, Nicolosi M, Regnard JF, Alifano M.

Lung. 2017 Dec;195(6):789-798. doi: 10.1007/s00408-017-0056-8. Epub 2017 Oct 11.

PMID:
29022070
49.

In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide.

Remark R, Merghoub T, Grabe N, Litjens G, Damotte D, Wolchok JD, Merad M, Gnjatic S.

Sci Immunol. 2016 Jul 14;1(1):aaf6925. doi: 10.1126/sciimmunol.aaf6925. Epub 2016 Jun 23.

PMID:
28783673
50.

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Franck N, Arrondeau J, Guégan S, Mansuet-Lupo A, Alexandre J, Damotte D, Avril MF, Dupin N, Aractingi S.

Invest New Drugs. 2017 Dec;35(6):842-847. doi: 10.1007/s10637-017-0476-6. Epub 2017 May 31.

PMID:
28569347

Supplemental Content

Loading ...
Support Center